{"component": "definition", "props": {"groups": [{"samples": [{"hash": "htD8TvNE9cf", "uri": "/contracts/htD8TvNE9cf#novartis", "label": "License Agreement (Legend Biotech Corp)", "score": 37.1861738535, "published": true}, {"hash": "a3ppdBQdM8D", "uri": "/contracts/a3ppdBQdM8D#novartis", "label": "Collaboration, Option and License Agreement (Monte Rosa Therapeutics, Inc.)", "score": 36.8466796875, "published": true}, {"hash": "iNpxxyOjC9H", "uri": "/contracts/iNpxxyOjC9H#novartis", "label": "License Agreement (Monte Rosa Therapeutics, Inc.)", "score": 36.2142372131, "published": true}], "snippet": "shall have the meaning set forth in the Preamble.", "size": 56, "snippet_links": [{"key": "the-preamble", "type": "clause", "offset": [36, 48]}], "hash": "2d89e8bd6146a6bf0155aa61c9436b2b", "id": 1}, {"samples": [{"hash": "cWBcOKyQkvX", "uri": "https://www.ftc.gov/system/files/documents/cases/order_to_maintain_assets.pdf", "label": "www.ftc.gov", "score": 8.786447525, "published": false}, {"hash": "e8PeqbySBBZ", "uri": "https://www.ftc.gov/system/files/documents/cases/decision_and_order.pdf", "label": "www.ftc.gov", "score": 8.3744010925, "published": false}, {"hash": "usRpbFuYml", "uri": "https://www.ftc.gov/system/files/documents/cases/150408novartisorder.pdf", "label": "www.ftc.gov", "score": 5.632443428, "published": false}], "snippet": "or \u201cRespondent\u201d means the following: Novartis AG, its directors, officers, employees, agents, representatives, successors, and assigns; and its joint ventures, subsidiaries, divisions, groups and affiliates in each case controlled by Novartis AG, and the respective directors, officers, employees, agents, representatives, successors, and assigns of each.", "size": 17, "snippet_links": [{"key": "novartis-ag", "type": "definition", "offset": [37, 48]}, {"key": "joint-ventures", "type": "definition", "offset": [144, 158]}, {"key": "each-case", "type": "definition", "offset": [210, 219]}, {"key": "by-novartis", "type": "clause", "offset": [231, 242]}], "hash": "2077dfb59228d0a17d2de9d1586f3d82", "id": 2}, {"samples": [{"hash": "58Ejg8ITMEk", "uri": "/contracts/58Ejg8ITMEk#novartis", "label": "Licensing Agreement", "score": 35.2836418152, "published": true}, {"hash": "h5Fj5g0X1lf", "uri": "/contracts/h5Fj5g0X1lf#novartis", "label": "Licensing Agreement", "score": 35.2466430664, "published": true}, {"hash": "2xP8fr3PAKJ", "uri": "/contracts/2xP8fr3PAKJ#novartis", "label": "Licensing Agreement", "score": 34.4048881531, "published": true}], "snippet": "means Novartis Pharma AG, a company incorporated under Swiss law, whose registered office is situated at \u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587 \u2587\u2587, \u2587\u2587\u2587\u2587 \u2587\u2587\u2587\u2587\u2587 and/or its Affiliates, as the context admits.", "size": 10, "snippet_links": [{"key": "novartis-pharma-ag", "type": "clause", "offset": [6, 24]}, {"key": "registered-office", "type": "clause", "offset": [72, 89]}, {"key": "the-context", "type": "clause", "offset": [159, 170]}], "hash": "ec74c1c2832273f072b915e8a0d23c86", "id": 3}, {"samples": [{"hash": "6C6jggl7goZ", "uri": "/contracts/6C6jggl7goZ#novartis", "label": "Investors\u2019 Rights Agreement (Ayala Pharmaceuticals, Inc.)", "score": 31.3381252289, "published": true}, {"hash": "eMRfcq3x95c", "uri": "/contracts/eMRfcq3x95c#novartis", "label": "Investors\u2019 Rights Agreement (Ayala Pharmaceuticals, Inc.)", "score": 31.1765918732, "published": true}, {"hash": "jEVVmoQjUH3", "uri": "/contracts/jEVVmoQjUH3#novartis", "label": "License and Collaboration Agreement (Arrowhead Research Corp)", "score": 22.9657764435, "published": true}], "snippet": "means Novartis Institutes for BioMedical Research, Inc.", "size": 9, "snippet_links": [{"key": "biomedical-research", "type": "clause", "offset": [30, 49]}], "hash": "1258d6c1fae7e4ca618966d5059035fa", "id": 4}, {"samples": [{"hash": "6vY4nP7xmDX", "uri": "/contracts/6vY4nP7xmDX#novartis", "label": "Collaboration and Option Agreement", "score": 35.0734024048, "published": true}, {"hash": "36wMUnRAHS9", "uri": "/contracts/36wMUnRAHS9#novartis", "label": "Collaboration and License Agreement (Ionis Pharmaceuticals Inc)", "score": 34.8343582153, "published": true}, {"hash": "lwg6mb8rfTi", "uri": "/contracts/lwg6mb8rfTi#novartis", "label": "Strategic Collaboration, Option and License Agreement (Ionis Pharmaceuticals Inc)", "score": 28.3511295319, "published": true}], "snippet": "has the meaning set forth in the Preamble of this Agreement.", "size": 8, "snippet_links": [{"key": "the-preamble", "type": "clause", "offset": [29, 41]}, {"key": "this-agreement", "type": "clause", "offset": [45, 59]}], "hash": "07f9208e3a4380257fdbdf3079a813c8", "id": 5}, {"samples": [{"hash": "hw15EVYL1Ac", "uri": "/contracts/hw15EVYL1Ac#novartis", "label": "Credit Agreement (Merus Labs International Inc.)", "score": 24.4113616943, "published": true}, {"hash": "e4iRBn9R8eL", "uri": "/contracts/e4iRBn9R8eL#novartis", "label": "Credit Agreement (PDL Biopharma, Inc.)", "score": 24.3921966553, "published": true}, {"hash": "c6ux8m9tnQ7", "uri": "/contracts/c6ux8m9tnQ7#novartis", "label": "Credit Agreement (Merus Labs International Inc.)", "score": 24.0034217834, "published": true}], "snippet": "means Novartis Pharma AG, a company organized under the laws of Switzerland, and its successors and assigns under the Novartis Letter of Credit.", "size": 7, "snippet_links": [{"key": "novartis-pharma-ag", "type": "clause", "offset": [6, 24]}, {"key": "company-organized", "type": "clause", "offset": [28, 45]}, {"key": "the-laws", "type": "definition", "offset": [52, 60]}, {"key": "successors-and-assigns", "type": "clause", "offset": [85, 107]}, {"key": "novartis-letter-of-credit", "type": "definition", "offset": [118, 143]}], "hash": "884afb2459db9b8e2c7bcd3ae384abe0", "id": 6}, {"samples": [{"hash": "ds6BvpTPPol", "uri": "/contracts/ds6BvpTPPol#novartis", "label": "Settlement Agreement", "score": 21.5276279449, "published": true}, {"hash": "3TRChXceBUv", "uri": "/contracts/3TRChXceBUv#novartis", "label": "Settlement Agreement", "score": 21.526971817, "published": true}, {"hash": "dTFsujE1PDL", "uri": "/contracts/dTFsujE1PDL#novartis", "label": "Settlement Agreement", "score": 21.2655715942, "published": true}], "snippet": "means Novartis Pharmaceuticals Corporation.", "size": 7, "snippet_links": [], "hash": "61739a791d04f7af0e9374b998ea0c08", "id": 7}, {"samples": [{"hash": "96UGijHRglv", "uri": "/contracts/96UGijHRglv#novartis", "label": "Sales and Promotional Services Agreement", "score": 31.3408622742, "published": true}, {"hash": "6G0nGghKQUT", "uri": "/contracts/6G0nGghKQUT#novartis", "label": "Sales and Promotional Services Agreement", "score": 31.3408622742, "published": true}, {"hash": "5bFiNmRt8U8", "uri": "/contracts/5bFiNmRt8U8#novartis", "label": "Sales Representative Services Agreement", "score": 31.3408622742, "published": true}], "snippet": "means, collectively, Novartis, AG and Novartis Consumer Health, Inc.", "size": 6, "snippet_links": [], "hash": "1cb25ad2cc8e440db933ccec060515b1", "id": 8}, {"samples": [{"hash": "l2q3fIV9JxT", "uri": "/contracts/l2q3fIV9JxT#novartis", "label": "Royalty Agreement", "score": 31.3408622742, "published": true}, {"hash": "hixE1Sd7Dl2", "uri": "/contracts/hixE1Sd7Dl2#novartis", "label": "Royalty Purchase Agreement", "score": 31.3408622742, "published": true}, {"hash": "cUfGETCmePS", "uri": "/contracts/cUfGETCmePS#novartis", "label": "Royalty Purchase Agreement (Titan Pharmaceuticals Inc)", "score": 22.8754272461, "published": true}], "snippet": "has the meaning set forth in the Background Statement.", "size": 5, "snippet_links": [{"key": "background-statement", "type": "clause", "offset": [33, 53]}], "hash": "a29b4bb05ae249a4f290291f2d7238f2", "id": 9}, {"samples": [{"hash": "PQpuuL4Alk", "uri": "/contracts/PQpuuL4Alk#novartis", "label": "Option Agreement (Adlai Nortye Ltd.)", "score": 34.3552360535, "published": true}, {"hash": "8elW4uesKGi", "uri": "/contracts/8elW4uesKGi#novartis", "label": "Asset Purchase Agreement (QLT Inc/Bc)", "score": 23.7378501892, "published": true}, {"hash": "bG3j8mrpSfw", "uri": "/contracts/bG3j8mrpSfw#novartis", "label": "Revenue Interests Assignment Agreement (Acorda Therapeutics Inc)", "score": 21.0, "published": true}], "snippet": "means Novartis Pharma AG.", "size": 5, "snippet_links": [{"key": "novartis-pharma-ag", "type": "clause", "offset": [6, 24]}], "hash": "e137446dc9f6f82c89fb602bdf71887c", "id": 10}], "next_curs": "ClUST2oVc35sYXdpbnNpZGVyY29udHJhY3RzcjELEhpEZWZpbml0aW9uU25pcHBldEdyb3VwX3Y1NiIRbm92YXJ0aXMjMDAwMDAwMGEMogECZW4YACAA", "definition": {"snippet": "shall have the meaning set forth in the Preamble.", "size": 242, "title": "Novartis", "id": "novartis", "examples": ["This Agreement will terminate automatically (and all licenses granted to Licensee hereunder will immediately terminate) upon termination of the corresponding licensed rights granted to IDEAYA by <strong>Novartis</strong> under the <strong>Novartis</strong> Agreement, subject to the provisions of Section 15.5 (Termination of <strong>Novartis</strong> Agreement).", "For clarity, in the event <strong>Novartis</strong> challenges the Net Sales amounts or calculations provided by IDEAYA and requests the gross amount invoiced for each Licensed Product on a country-by-country basis in the Territory, then Licensee shall, |US-DOCS\\163899140.5|| within [***], provide IDEAYA with the requested gross amount invoiced for each Licensed Product, on a country-by-country basis.", "IDEAYA shall not terminate the <strong>Novartis</strong> Agreement pursuant to Section 11.4 (Termination by IDEAYA Without Cause) of the <strong>Novartis</strong> Agreement without consulting with Licensee in accordance with Section 2.6(a) (<strong>Novartis</strong> Agreement).", "IDEAYA shall provide the Licensee with a copy of such communications received from <strong>Novartis</strong> in subclause (ii), or a written summary if such communication is oral.", "Prior to such audit, the auditor shall enter into a confidentiality agreement containing customary terms and conditions with the Parties and <strong>Novartis</strong> (as applicable) that has obligations of confidentiality and non-use no less restrictive than those set forth Article 11 (Confidentiality) and that limits the disclosure and use of such information by such auditor to authorized representatives of the Parties and <strong>Novartis</strong> for the purposes of this Section 9.7 (Records and Audit).", "IDEAYA shall notify Licensee of any (i) material breach, threat of termination or notice of or actual termination of the <strong>Novartis</strong> Agreement, or (ii) communication received from <strong>Novartis</strong> alleging any material breach, default or other issue relating to the <strong>Novartis</strong> Agreement, in each case ((i)-(ii)), that would reasonably be expected to affect Licensee\u2019s rights to the Licensed Product or Licensed IP granted under this Agreement.", "IDEAYA shall ensure that any right granted to or obligations imposed on Licensee in this Agreement comply with the applicable provisions of the <strong>Novartis</strong> Agreement, and Licensee shall ensure that it and its Affiliates and its and their Sublicensees comply in all material respects with all terms and conditions of this Agreement that are necessary for IDEAYA\u2019s compliance with the <strong>Novartis</strong> Agreement."], "related": [["merck", "Merck", "Merck"], ["bms", "BMS", "BMS"], ["isis", "ISIS", "ISIS"], ["gsk", "GSK", "GSK"], ["pfizer", "Pfizer", "Pfizer"]], "related_snippets": [], "updated": "2026-03-14T06:33:37+00:00"}, "json": true, "cursor": ""}}